New drug aims to fight advanced stomach cancer when standard treatments fail

NCT ID NCT07692204

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This phase 2 trial tests an experimental drug called SAR445877 in adults with advanced gastric or gastroesophageal junction cancer that has worsened after at least one prior treatment. The study includes about 30 participants and looks at whether the drug can shrink tumors. It is open-label, meaning everyone knows they are receiving the drug, and the drug is given by infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR445877
What this could lead to: If effective, this could provide a new treatment option for people with advanced gastric or gastroesophageal junction cancer who have few alternatives.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTROESOPHAGEAL JUNCTION CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus Esophageal Neoplasms gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER OESOPHAGEAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Investigational Site Number : 1560001
RECRUITING

Shanghai, 200131, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.